Torii Nihonbashi Bldg.
4-1, Nihonbashi-Honcho 3-chome Chuo-ku
Tokyo 103-8439
Japan
81 3 3231 6811
https://www.torii.co.jp
Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 583
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Goichi Matsuda | President, CEO & Representative Director | N/A | N/A | 1967 |
Yukihiro Takashima | General Manager of Finance & Accounting Department | N/A | N/A | N/A |
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. In addition, it is engaged in real estate rental business. The company markets its products primarily through medical representatives for medical professionals. The company has a collaboaration with ALK-Abelló A/S to develop, market and distribute ALK's allergy immunotherapy tablet for the treatment of grass pollen allergy. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.
Torii Pharmaceutical Co., Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.